Wanbury Ltd banner

Wanbury Ltd
NSE:WANBURY

Watchlist Manager
Wanbury Ltd Logo
Wanbury Ltd
NSE:WANBURY
Watchlist
Price: 269.97 INR 3.38% Market Closed
Market Cap: ₹9.4B

Relative Value

WANBURY doesn't have a meaningful market cap.

The Relative Value of one WANBURY stock under the Base Case scenario is hidden INR. Compared to the current market price of 269.97 INR, Wanbury Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

WANBURY Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

WANBURY Competitors Multiples
Wanbury Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Wanbury Ltd
NSE:WANBURY
9.4B INR 1.4 14.6 10.1 11.6
US
Eli Lilly and Co
NYSE:LLY
984.9B USD 15.1 47.8 32.2 34.3
US
Johnson & Johnson
NYSE:JNJ
592.6B USD 6.3 22 15.3 18.8
CH
Roche Holding AG
SIX:ROG
291.5B CHF 4.8 31.3 13.2 15.4
UK
AstraZeneca PLC
LSE:AZN
235.1B GBP 5.5 31.5 17.4 24.5
CH
Novartis AG
SIX:NOVN
243.5B CHF 5.6 22.5 13.9 17.8
US
Merck & Co Inc
NYSE:MRK
306B USD 4.7 16.7 10.4 12.2
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 3.7 11.3 8.3 9.8
US
Pfizer Inc
NYSE:PFE
152.2B USD 2.4 19.7 7.3 9.8
US
Bristol-Myers Squibb Co
NYSE:BMY
123.2B USD 2.6 17.5 7.3 9
P/E Multiple
Earnings Growth PEG
IN
Wanbury Ltd
NSE:WANBURY
Average P/E: 23.5
14.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.8
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.3
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.5
26%
1.2
CH
Novartis AG
SIX:NOVN
22.5
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.7
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
7%
1.6
US
Pfizer Inc
NYSE:PFE
19.7
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Wanbury Ltd
NSE:WANBURY
Average EV/EBITDA: 42.6
10.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.2
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.2
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.4
11%
1.6
CH
Novartis AG
SIX:NOVN
13.9
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.3
7%
1.2
US
Pfizer Inc
NYSE:PFE
7.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-12%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Wanbury Ltd
NSE:WANBURY
Average EV/EBIT: 90.8
11.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.3
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.8
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.4
6%
2.6
UK
AstraZeneca PLC
LSE:AZN
24.5
24%
1
CH
Novartis AG
SIX:NOVN
17.8
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.2
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
8%
1.2
US
Pfizer Inc
NYSE:PFE
9.8
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9
-6%
N/A